N-(imidazo[1,2-a]pyridin-6-ylmethyl)-N-methyl-5-(2-methyl-4-(1,2,4-trimethyl-1H-imidazol-5-yl)phenyl)-1,3,4-oxadiazol-2-amine

ID: ALA4856195

PubChem CID: 164610821

Max Phase: Preclinical

Molecular Formula: C24H25N7O

Molecular Weight: 427.51

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cc1cc(-c2c(C)nc(C)n2C)ccc1-c1nnc(N(C)Cc2ccc3nccn3c2)o1

Standard InChI:  InChI=1S/C24H25N7O/c1-15-12-19(22-16(2)26-17(3)30(22)5)7-8-20(15)23-27-28-24(32-23)29(4)13-18-6-9-21-25-10-11-31(21)14-18/h6-12,14H,13H2,1-5H3

Standard InChI Key:  ZNGCWFPZUBLLOJ-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 32 36  0  0  0  0  0  0  0  0999 V2000
    1.4540  -29.1343    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4540  -28.3071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1621  -27.8926    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.8741  -28.3093    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8741  -29.1343    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1621  -29.5427    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5880  -29.5479    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3031  -29.1364    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.0171  -29.5500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1009  -30.3705    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.9076  -30.5431    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.3212  -29.8292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7700  -29.2154    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.1418  -29.7441    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6235  -30.4135    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4434  -30.3289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7807  -29.5750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2921  -28.9050    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4739  -28.9930    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9873  -28.3268    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6013  -29.4888    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1528  -30.1009    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9814  -30.9080    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.8629  -29.6801    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.8203  -28.9448    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0133  -28.7734    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.6773  -28.0198    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.4334  -28.3927    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3031  -28.3113    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9868  -27.0910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1702  -27.0101    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8411  -27.7616    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  2  3  1  0
  4  3  1  0
  5  4  2  0
  6  5  1  0
  1  6  2  0
  5  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13  9  1  0
 12 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 14  1  0
 19 20  1  0
 17 21  1  0
 21 22  2  0
 22 23  1  0
 22 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  1  0
 21 26  1  0
 25 28  1  0
  8 29  1  0
  3 30  1  0
 30 31  2  0
 31 32  1  0
 32  2  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA4856195

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 427.51

Molecular Weight (Monoisotopic): 427.2121

AlogP: 4.35

#Rotatable Bonds: 5

Polar Surface Area: 77.28

Molecular Species: NEUTRAL

HBA: 8

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 6.73

CX LogP: 2.72

CX LogD: 2.64

Aromatic Rings: 5

Heavy Atoms: 32

QED Weighted: 0.42

Np Likeness Score: -1.56

References

1. McCoull W, Boyd S, Brown MR, Coen M, Collingwood O, Davies NL, Doherty A, Fairley G, Goldberg K, Hardaker E, He G, Hennessy EJ, Hopcroft P, Hodgson G, Jackson A, Jiang X, Karmokar A, Lainé AL, Lindsay N, Mao Y, Markandu R, McMurray L, McLean N, Mooney L, Musgrove H, Nissink JWM, Pflug A, Reddy VP, Rawlins PB, Rivers E, Schimpl M, Smith GF, Tentarelli S, Travers J, Troup RI, Walton J, Wang C, Wilkinson S, Williamson B, Winter-Holt J, Yang D, Zheng Y, Zhu Q, Smith PD..  (2021)  Optimization of an Imidazo[1,2-a]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy.,  64  (18.0): [PMID:34478292] [10.1021/acs.jmedchem.1c00920]

Source

Source(1):

• Scientific Literature